{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:52:36Z","timestamp":1788580356598,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.ejphar.2012.05.043","type":"journal-article","created":{"date-parts":[[2012,6,19]],"date-time":"2012-06-19T22:01:00Z","timestamp":1340143260000},"page":"176-182","source":"Crossref","is-referenced-by-count":11,"title":["Benzenesulfonamide attenuates monocrotaline-induced pulmonary arterial hypertension in a rat model"],"prefix":"10.1016","volume":"690","author":[{"given":"Gisele","family":"Zapata-Sudo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana Braga","family":"Pontes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaqueline Soares da","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00eddia Moreira","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle Karine da Costa","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliezer Jesus","family":"Barreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto Takashi","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2012.05.043_bib1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/01.RES.0000111804.34509.94","article-title":"Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats","volume":"94","author":"Abe","year":"2004","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2012.05.043_bib2","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1161\/01.CIR.102.22.2781","article-title":"Primary pulmonary hypertension: a vascular biology and translational research \u201cWork in progress\u201d","volume":"102","author":"Archer","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2012.05.043_bib3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1006\/phrs.1999.0481","article-title":"Endotelial dysfunction and hypertensive vasoconstriction","volume":"40","author":"Arti\u00f1ano","year":"1999","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2012.05.043_bib4","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2147\/VHRM.S4711","article-title":"RhoA\/Rho-kinase signaling: a therapeutic target in pulmonary hypertension","volume":"5","author":"Barman","year":"2009","journal-title":"Vasc. Health Risk Manage."},{"key":"10.1016\/j.ejphar.2012.05.043_bib5","doi-asserted-by":"crossref","first-page":"S252","DOI":"10.1038\/sj.bjp.0706495","article-title":"Phosphodiesterase inhibitors","volume":"147","author":"Boswell-Smith","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2012.05.043_bib7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/bjp.2008.247","article-title":"Mechanisms of augmented vasoconstriction induced by 5-hydroxytryptamine in aortic rings from spontaneously hypertensive rats","volume":"155","author":"Budzyn","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2012.05.043_bib8","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1253\/circj.72.825","article-title":"Cilostazol therapy attenuates monocrotaline-induced pulmonary arterial hypertension in rat model","volume":"72","author":"Chang","year":"2008","journal-title":"Circ. J."},{"key":"10.1016\/j.ejphar.2012.05.043_bib9","first-page":"389","article-title":"Pulmonary artery adventitial changes and venous involvement in primary pulmonary hypertension","volume":"146","author":"Chazova","year":"1995","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejphar.2012.05.043_bib10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1152\/physrev.1999.79.2.387","article-title":"Signaling mechanisms underlying the vascular myogenic response","volume":"79","author":"Davis","year":"1999","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejphar.2012.05.043_bib11","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/00003246-200003000-00031","article-title":"Additive effects of inhaled nitric oxide and intravenous milrinone in experimental pulmonary hypertension","volume":"28","author":"Deb","year":"2000","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.ejphar.2012.05.043_bib12","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/303059","article-title":"Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene","volume":"67","author":"Deng","year":"2000","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ejphar.2012.05.043_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1523-1755.1999.00233.x","article-title":"Cyclic-3\u2032,5\u2032-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney","volume":"55","author":"Dousa","year":"1999","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2012.05.043_bib15","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1172\/JCI200112805","article-title":"Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension","volume":"108","author":"Eddahibi","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2012.05.043_bib16","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1067\/mai.2001.119555","article-title":"Cyclic nucleotide phosphodiesterases","volume":"108","author":"Essayan","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejphar.2012.05.043_bib17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0014-2999(01)01335-8","article-title":"Synergistic interaction of diazepam with 3\u2032,5\u2032-cyclic adenosine monophosphate-elevating agents on rat aortic rings","volume":"428","author":"Galindo","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2012.05.043_bib18","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(02)11024-5","article-title":"Sildenafil for treatmente of lung fibrosis and pulmonary hypertension: a randomized controlled trial","volume":"360","author":"Ghofrani","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2012.05.043_bib19","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jacc.2009.04.006","article-title":"Inflammation, growth factors, and pulmonary vascular remodeling","volume":"54","author":"Hassoun","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2012.05.043_bib20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0002-9343(99)80156-9","article-title":"Increased plasma serotonin in primary pulmonary hypertension","volume":"99","author":"Herv\u00e9","year":"1995","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejphar.2012.05.043_bib21","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMra040291","article-title":"Treatment of pulmonary arterial hypertension","volume":"351","author":"Humbert","year":"2004","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.ejphar.2012.05.043_bib23","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0163-7258(90)90063-8","article-title":"Activation and pulmonary toxicity of pyrrolizidine alkaloids","volume":"47","author":"Huxtable","year":"1990","journal-title":"Pharmac. Ther."},{"key":"10.1016\/j.ejphar.2012.05.043_bib24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1124\/jpet.108.148742","article-title":"Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats","volume":"330","author":"Izikki","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2012.05.043_bib25","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1510\/icvts.2006.147033","article-title":"Oral sildenafil prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats","volume":"6","author":"Liu","year":"2007","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"key":"10.1016\/j.ejphar.2012.05.043_bib26","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.lfs.2004.10.009","article-title":"Endothelium-dependent and \u2013independent vasorelaxation by a theophylline derivative MCPT: roles of cyclic nucleotides, potassium channel opening and phosphodiesterase inhibition","volume":"76","author":"Lo","year":"2005","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2012.05.043_bib27","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/0006-2952(86)90333-3","article-title":"Selective inhibition of cyclic nucleotide phosphodiesterase of human, bovine and rat aorta","volume":"35","author":"Lugnier","year":"1986","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2012.05.043_bib28","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1440-1681.2007.04618.x","article-title":"Amlodipine prevents monocrotaline-induced pulmonary arterial hypertension and prolongs survival in rats independent of blood pressure lowering","volume":"34","author":"Mawatari","year":"2007","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.ejphar.2012.05.043_bib29","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1161\/CIRCULATIONAHA.109.192230","volume":"119","author":"McLaughlin","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2012.05.043_bib30","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1161\/01.CIR.0000016641.12984.DC","article-title":"Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide","volume":"105","author":"Michelakis","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2012.05.043_bib31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0014-2999(95)00355-O","article-title":"Isoenzymes of cyclic nucleotide phosphodiesterase in the human aorta: characterization and the effects of E4021","volume":"284","author":"Miyahara","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2012.05.043_bib32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0014-2999(02)01339-0","article-title":"Sildenafil and T-1032, phosphodiesterase type 5 inhibitors, showed a different vasorelaxant property in the isolated rat aorta","volume":"440","author":"Mochida","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2012.05.043_bib34","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1365-2125.2006.02658.x","article-title":"Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension","volume":"62","author":"Patterson","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2012.05.043_bib35","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI17500","article-title":"Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension","volume":"111","author":"Petkov","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2012.05.043_bib36","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1161\/01.CIR.80.5.1198","article-title":"Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the national heart, lung, and blood institute, primary pulmonary hypertension registry","volume":"80","author":"Pietra","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2012.05.043_bib37","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrd893","article-title":"Phosphodiesterase 5 inhibitors: current status and potential applications","volume":"1","author":"Rotella","year":"2002","journal-title":"Nat. Drugs Discovery"},{"key":"10.1016\/j.ejphar.2012.05.043_bib39","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2003.10.056","article-title":"Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo-controlled, double-blind, crossover study","volume":"43","author":"Sastry","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2012.05.043_bib40","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1161\/01.RES.0000126050.41296.8E","article-title":"Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3\/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension","volume":"94","author":"Schermuly","year":"2004","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2012.05.043_bib41","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/00005344-200203000-00001","article-title":"Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases","volume":"39","author":"Shimokawa","year":"2002","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2012.05.043_bib43","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jacc.2009.04.012","article-title":"Updated clinical classification of pulmonary hypertension","volume":"54","author":"Simonneau","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2012.05.043_bib44","unstructured":"Sun, D., Perkins, E.L., Tugendreich, S., 2003. Modulators of Rho C activity. WO 03\/043578\u2014PCT\/US02\/37098."},{"key":"10.1016\/j.ejphar.2012.05.043_bib45","doi-asserted-by":"crossref","first-page":"487S","DOI":"10.1378\/chest.132.4_MeetingAbstracts.487a","article-title":"Survival of patients with pulmonary arterial hypertension in the current era: validation of the national institute of health (NIH) risk stratification equation","volume":"132","author":"Thenappan","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.ejphar.2012.05.043_bib46","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejphar.2010.07.028","article-title":"Mechanisms of relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in rat tracheal smooth muscle","volume":"645","author":"Toque","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2012.05.043_bib47","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJM200108023450503","article-title":"Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia","volume":"345","author":"Trembath","year":"2001","journal-title":"NEJM"},{"key":"10.1016\/j.ejphar.2012.05.043_bib48","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1164\/ajrccm.159.6.9804054","article-title":"Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension","volume":"159","author":"Tuder","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejphar.2012.05.043_bib49","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1164\/rccm.200411-1587OC","article-title":"Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells","volume":"172","author":"Wharton","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejphar.2012.05.043_bib50","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1084\/jem.20052267","article-title":"Carbon monoxide reverses established pulmonary hypertension","volume":"203","author":"Zuckerbraun","year":"2006","journal-title":"J. Exp. Med."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429991200502X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429991200502X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,30]],"date-time":"2019-06-30T04:04:52Z","timestamp":1561867492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001429991200502X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":44,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S001429991200502X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2012.05.043","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}